The cell's endogenous antioxidant system is vital to maintenance of redox homeostasis. Despite its 3 central role in normal and pathophysiology, no non-invasive tools exist to measure this system in 4 patients. The cystine/glutamate antiporter system xcmaintains the balance between intracellular 5 reactive oxygen species and antioxidant production through the provision of cystine, a key 6 precursor in glutathione biosynthesis. Here we show that tumor cell retention of a system xc --7 specific positron emission tomography radiotracer, (S)-4-(3-[ 18 F]fluoropropyl)-L-glutamic acid 8 ([ 18 F]FSPG), decreases in proportion to levels of oxidative stress following treatment with a range 9 of redox-active compounds. The decrease in [ 18 F]FSPG retention correlated with a depletion of 10 intracellular cystine resulting from increased de novo glutathione biosynthesis, shown through [U-11 13 C6, U-15 N2]cystine isotopic tracing. In vivo, treatment with the chemotherapeutic doxorubicin 12 decreased [ 18 F]FSPG tumor uptake in a mouse model of ovarian cancer, coinciding with markers 13 of oxidative stress but preceding tumor shrinkage and decreased glucose utilization. Having 14 already been used in pilot clinical trials, [ 18 F]FSPG PET could be rapidly translated to the clinic 15 as an early redox indicator of tumor response to treatment. 16
INTRODUCTION 1 2
Mammalian cells have developed an exquisite system of biochemical processes with which to 3 maintain redox homeostasis. The overall purpose of this system is to prevent damage from 4 unregulated redox reactions. For example, harmful reactive oxygen species (ROS) generated 5 during oxidative phosphorylation are buffered by the activity of multiple enzymes including 6 superoxide dismutase, catalase, and glutathione peroxidase, which convert ROS to increasingly 7 benign products. Other toxic redox-active compounds include exogenous electrophiles, which can 8 be neutralized by an array of intracellular antioxidants, such as glutathione (GSH) and thioredoxin 9 (Trx), along with associated oxidoreductase enzymes. While these mechanisms are usually 10 sufficient to maintain redox homeostasis, prolonged or elevated exposure to ROS or exogenous 11 electrophiles can result in damage to DNA, proteins and cell membranes (reviewed in (1) ). The 12 consequences of redox dysregulationcumulatively referred to as oxidative stressplay an 13 important role in a myriad of diseases, including cancer (2, 3), arthritis (4), cardiovascular disease 14 (5) , Alzheimer's disease and Parkinson's disease (6) . 15 16 Cancer cells reprogram their metabolism to meet the energetic and biosynthetic demands 17 accompanying elevated rates of replication (7) . A common consequence of this metabolic 18 adaptation is an elevation in ROS (8). To avoid the cytotoxicity associated with high ROS levels, 19 cancer cells can adapt by upregulating key antioxidant molecules such as GSH and Trx (9) . 20
Additionally, many chemotherapeutic agents are known to produce oxidative stress, as evidenced 21 by elevation of lipid peroxidation products, diminished radical-trapping capacity of blood plasma, 22 decreased plasma levels of antioxidants such as vitamin E, vitamin C, and β-carotene, and the 23
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Author Manuscript Published OnlineFirst on November 6, 2018; DOI: 10.1158/0008-5472. CAN-18-2634 limiting substrate in the biosynthesis of GSH (29), the cell's most abundant small molecule 1 antioxidant (30) . System xc --derived cystine represents one of the primary sources of intracellular 2 cysteine, particularly under conditions of oxidative stress when system xcexpression and cysteine 3 demand are increased (31) . High levels of system xcexpression result in increased cystine influx 4 (32) and GSH biosynthesis (33), processes which utilize intracellular glutamate as an exchange 5 partner and biosynthetic precursor, respectively. This xc -/cystine-mediated shunting of glutamate 6 away from anaplerotic reactions is thought to be the driving force behind reduced glutamine 7 dependence observed in tumors when compared to cells grown in culture (32). 8 9 Specific uptake via system xctransport places [ 18 F]FSPG at a central position within the cell's 10 antioxidant system. Accordingly, we hypothesized that [ 18 F]FSPG PET would provide a useful 11 tool for in vivo imaging of cellular redox status. Moreover, the fact that [ 18 F]FSPG has already 12 been used in pilot clinical trials provides the possibility for its rapid translation to human redox 13 imaging. In this study we characterize changes in [ 18 F]FSPG retention in response to oxidant and 14 antioxidant treatments. Using a metabolomics approach, we then address the molecular 15 mechanisms underlying the observed changes in [ 18 F]FSPG uptake. Finally, we evaluate the utility 16 of [ 18 F]FSPG for in vivo imaging of tumor redox status in a mouse model of ovarian cancer, and 17 assess its potential for the detection of redox changes that occur during chemotherapy . 18 Research.
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MATERIALS AND METHODS 1 2

Cell lines 3
Human ovarian cancer A2780 cells were obtained from Sigma-Aldrich, PEO1 and PEO14 cells 4 from Public Health England Culture Collections, and SKOV3 cells were donated by Dr. Anil K. 5
Sood (MD Anderson Cancer Centre, USA). A2780 and SKOV3 cells were selected as well-6 characterized cell models of human ovarian cancer, with patient-derived PEO1 and PEO14 cells 7 taken from two patients with high grade serous ovarian cancer that were classified as 8 chemotherapy-sensitive. A2780 and SKOV3 cells were cultured in RPMI media supplemented 9 with 10% FBS. PEO1 and PEO14 cells were cultured in RMPI media supplemented with 10% 10 FBS and 2 mM sodium pyruvate. All cell lines were maintained at 37 °C and 5% CO2 in a 11 humidified atmosphere, with mycoplasma testing performed on a monthly basis. Cells were 12 authenticated by short tandem repeat profiling just prior to submission and kept within 10-15 13 passages of the original frozen vial. 14 15
Animal subjects 16
Female immunodeficient nu/nu BALB/c mice (8-10 weeks) were used and were obtained from 17 
Cell drug treatments 2
Except where specifically noted, cells were seeded 24 h prior to treatment at a density of 5.3  10 4 3 cells/cm 2 (corresponding to 5  10 5 cells per well on a 6-well plate). For 24 h treatments, seeding 4 densities were: A2780, 5.3  10 4 cells/cm 2 ; PEO1, 2.6  10 4 cells/cm 2 ; PEO14, 1.3  10 4 cells/cm 2 . 5
Fresh media was provided at least 1 h prior to drug treatments, and for treatment durations 24 h 6 for longer, fresh media including drug was given 1 h prior to any experimental determinations. 7 TBHP was administered 1 h prior to assay at a final concentration of 200 µM. NAC was added 1h 8 prior to TBHP administration (2 h total treatment duration) at a final concentration of 5 mM. Cells 9 were treated with butein (BUT) and diethyl maleate (DEM) 24 h prior to assay, whereas Doxil 10 (DOX) was administered 72 h prior to assay. All remaining drugs were added 1 h prior to assay. 11 
Measurement of intracellular GSH 2
Cells were seeded at a density of 4  10 4 cells per well in 96-well plates. Following drug treatment, 3 medium was aspirated and the cells were rapidly washed on ice with ice-cold PBS (3  200 µL). 4 GSH measurements were then carried out directly on the plate using the GSH/GSSG-Glo Assay 5 kit (Promega, UK) according to manufacturer's instructions. Estimates of reduced GSH were 6 obtained as the difference between total and oxidised GSH. Data were expressed as the ratio of 7 GSSG:GSH. 8 9
Measurement of intracellular glutamate 10
To examine the relationship between intracellular glutamate and [ 18 F]FSPG retention, cells were 11 incubated for various durations in glutamine/FBS-free media. After all treatments, the medium 12 was aspirated and the cells were washed with 1 mL of warmed Dulbecco's phosphate buffered 13 saline (DPBS). The cells were trypsinized and washed three times by centrifugation (600  g, 4 °C 14 for 3 min) and resuspension in ice-cold PBS. The final cell pellet was resuspended in 200 µL of 15 ice-cold glutamate assay buffer (Biovision). The cells were then placed on ice and lysed by 16 sonication using a Hielscher UP50H ultrasonic processor for three sets of six 0.5 s pulses. The 17 lysed sample was then centrifuged at 15,000  g, 4 °C for 10 min, and the supernatant analyzed 18 using the Biovision Glutamate Colorimetric Assay according to manufacturer's instructions. 19
Protein content was determined using the Pierce BCA Protein Assay Kit (Thermo Fisher) and the 20 glutamate content was expressed as nmol/mg protein. 21
22
Metabolomics measurements 23
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Western blotting 3
Western blot analysis was accomplished using previous described methodology (34) , adapted for 4 use with the iBind Flex system for primary and secondary antibody immunoblotting, according to 5 the manufacturer's instructions. Monoclonal antibodies to rabbit anti-human system xc -, GLS, 6 KGA, NRF2, p53, GCL, caspase-3 and cleaved-caspase-3 (1:1000 dilution) were used for western 7 blot analysis of both A2780 cell lysates and tumor lysates. Actin was used as a loading control for 8 all experiments (1:1000 dilution). 9
10 In vivo tumor model 11
Immunocompromised Balb/c nude mice received a subcutaneous injection of 5 ×10 6 A2780 cells 12 in 100 µL PBS at a location approximately between the scapulae on the dorsal surface. Daily 13 caliper measurements were made on the growing tumors. The volume was estimated by the 14 formula: (length × width × depth × π)/6. When any individual tumor reached 100 mm 3 in volume 15 (day 0), the animal was assigned to one of three groups: untreated, 24 h Doxil treatment, or 6 day 16 Doxil treatment. Untreated animals received no treatment, animals in the 24 h Doxil group 17 received a single intraperitoneal injection of 10 mg/kg Doxil on day 0, and the animals in the 6 d 18
Doxil group received Doxil on days 0, 2 and 5. PET experiments with either [ 18 F]FSPG or 19 [ 18 F]FDG were performed on days 0, 1 and 6 in the untreated, 24 h, and 6 d Doxil treatment groups, 20 respectively. In the [ 18 F]FSPG experiment, each animal was scanned at days 0, 1 and 6, whereas 21 in the [ 18 F]FDG experiment a separate group of animals was scanned on each of the three days. 22
Immediately following [ 18 F]FDG scanning, the tumors were excised, divided into four 23 approximately equal sized pieces, weighed, rapidly frozen in liquid nitrogen and stored at -80 °C 1 for ex vivo analysis. 2 3 Ex vivo analysis of tumor tissue samples 4 Impact-resistant tubes containing Lysing Matrix D (MP Biomedicals) were pre-loaded with 300 5 µL GSH buffer (Promega), with or without 1 mM N-ethyl maleimide (NEM) for determination of 6 GSSG or total GSH, respectively. Separate tubes were pre-loaded with 500 µL of RIPA buffer 7
containing Halt protease and phosphatase inhibitor cocktail (ThermoFisher Scientific) for 8 preparation of samples for Western blot analysis. Into these tubes were placed the tissue samples 9 and the tissue was lysed by rapid shaking for 15 s at 4 °C using a FastPrep-24 homogenizer (MP 10 Biomedicals). The resulting lysates were centrifuged at 15,000  g, 4 °C for 10 min to pellet 11 insoluble debris. The supernatant was analyzed for total glutamate, GSH (oxidized and reduced), 12 and the expression of specific proteins, as described above. Metabolite levels were normalized to 13 sample protein content as described above. 14 15
Radiotracer synthesis 16
The radiotracer [ 18 F]FSPG was prepared using an automated HotBox III module (Scintomics, 17 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Radiotracer cell uptake experiments 1
Cells were seeded at the appropriate density in 6-well plates (see above). Drug treatments, in 2 triplicate, were carried out as described above, after which 185 kBq of either [ 18 F]FSPG or 3 [ 18 F]FDG was added. After a 60 min uptake period at 37 °C cells were processed according to 4 previously-described methodology (36). Radioactivity in samples was expressed as a percentage 5 of the administered dose per mg protein. 6 7
Positron emission tomography experiments 8
Mice were anaesthetized with isoflurane (2.5% in oxygen) and maintained at 37 °C using an air-9 heated scanning bed. A cannula was inserted in the tail vein and a 3.7 MBq bolus of either 10 [ 18 F]FSPG or [ 18 F]FDG was administered in approximately 100 µL of PBS. Mice were then 11 allowed to recover from anaesthesia, and forty minutes later a 20 min PET acquisition was 12 performed on a Mediso nanoScan PET/CT system under isoflurane anaesthesia (1.5-2%) . 13
Attenuation correction was done using CT data (50 kVp, 480 projections) and static reconstruction 14 was done using the Tera-Tomo 3D reconstruction algorithm, with 4 iterations, 6 subsets, a binning 15 window of 400-600 keV, and a voxel size of 0.4 mm. The resulting reconstructed images were 16 analyzed using VivoQuant software (v. 2.5, Invicro Ltd.). Tumor volumes of interest were 17 compiled from sequential 2D regions of interest drawn on the CT images. The radioactivity 18 concentration in each volume of interest was expressed as a percentage of the injected dose per 19 mL of tissue volume (%ID/mL). Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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Statistical tests and linear regression analyses were performed using GraphPad Prism software (v. 2 10.1). Comparisons were considered statistically significant went p < 0.05. In all analyses, 3
Bonferroni multiple comparison corrections were applied when appropriate. For normalized flow 4 cytometric data, fold change in median fluorescence intensity was assessed using single sample 5 two-tailed t tests (versus unity). For correlation plots the measure of goodness-of-fit (R 2 ) was 6 determined, with an F test used to assess whether the line of regression was significantly different 7 from zero. For all other data, standard two-tailed t tests were used. 8
Research. A2780 ovarian cancer cells were treated with the oxidant tert-butyl hydroperoxide (TBHP), alone 6 or following pre-treatment with the antioxidant N-acetylcysteine (NAC), and compared with 7 untreated cells. In response to TBHP alone, cells displayed several hallmark features of oxidative 8 stress: levels of ROS, as measured by the fluorophore CellROX Orange, were elevated 5.6-fold (p 9 < 0.0001; Fig. 1A) , and the ratio of oxidized (GSSG) to reduced GSH was doubled ( Fig. 1B) . In 10 addition, protein expression of the antioxidant transcription factor Nrf2 and the cell cycle regulator 11 p53 were increased upon TBHP treatment (Fig. 1C) , indicating transcriptional up-regulation of 12 cellular antioxidant defenses, DNA damage and potential cell cycle arrest. TBHP, however, did 13 not induce cell death at this dose, as shown by an absence of cleaved caspase-3 and by flow 14 cytometric measurements using annexin V and Sytox Red (Fig. 1D) . In contrast, NAC treatment 15 alone did not alter ROS levels (Fig. 1A) or the ratio of GSSG to GSH ( Fig. 1B) , suggesting low 16 levels of oxidative stress under baseline cell culture conditions. Following NAC pre-treatment, 17 however, TBHP-mediated oxidative stress was greatly diminished, with the levels of ROS and the 18 ratio of GSSG to GSH similar to untreated cells ( Fig. 1A and B) . 19 20 We next examined the accumulation of [ 18 F]FSPG under TBHP/NAC treatment conditions ( Fig.  21   1E) . Following TBHP-induced oxidative stress, [ 18 F]FSPG cell-associated radioactivity was 22 decreased from 11.0 ± 0.6 % radioactivity/mg protein in untreated cells, to 5.9 ± 1.6 % 23
on November 6, 2018. © 2018 American Association for Cancer cancerres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. radioactivity/mg protein following TBHP treatment (p < 0.001; Fig. 1F ). Decreased [ 18 F]FSPG 1 accumulation was also seen in PEO1, PEO14 and SKOV3 ovarian cancer cells upon TBHP 2 treatment, where it was also associated with increased ROS, demonstrating that [ 18 F]FSPG's 3 sensitivity to redox status was not cell line-specific (Supplementary Fig. S1 ). In A2780 cells, 4 treatment with NAC resulted in a doubling of [ 18 F]FSPG cell-associated radioactivity when 5 administered alone (11.0 ± 0.6 % radioactivity/mg protein in untreated cells and 22.6 ± 3.5 % 6 radioactivity/mg protein following NAC treatment; p < 0.0001). When given as a pretreatment , 7 NAC prevented the decrease in [ 18 F]FSPG accumulation seen with TBHP administration (Fig.  8   1F) . By comparison, [ 18 F]2-fluoro-2-deoxy-D-glucose ([ 18 F]FDG) uptake, a marker of glucose 9 utilization, was decreased by TBHP, but this effect was not prevented by NAC pre-treatment, nor 10 was there any effect seen following NAC treatment alone (Fig. 1G) . 11 12
Decreased [ 18 F]FSPG accumulation is correlated with the degree of oxidative stress 13
In order to investigate whether changes in [ 18 F]FSPG accumulation robustly reflected drug-14 induced oxidative stress, we identified a panel of mechanistically-diverse redox-active compounds 15 and measured their impact on ROS and corresponding changes in [ 18 F]FSPG uptake (Fig. 2) . The 16 compounds selected were diethyl maleate, an electrophile which causes GSH depletion; antimycin 17
A, an electron transport chain complex III inhibitor; rotenone, an electron transport chain complex 18 I inhibitor; auranofin, a thioredoxin reductase 1 inhibitor; and butein, an inhibitor of signal 19 transducer and activator of transcription 3 (STAT3). In A2780 cells, the magnitude of treatment-20 induced ROS varied considerably between these compounds, ranging from a 50 % to 330 % 21 increase ( Fig. 2A) . The changes in ROS were paralleled by decreases in [ 18 F]FSPG accumulation, 22 ranging from 15 % to 78 % relative to vehicle-treated control cells (Fig. 2B) . Importantly, there 23
Author Manuscript Published OnlineFirst on November 6, 2018; DOI: 10.1158/0008-5472. CAN-18-2634 was a strong correlation between ROS induction and [ 18 F]FSPG retention (r = -0.92, R 2 = 0.85, p 1 = 0.009; Fig. 2C) . Having determined that drug-induced oxidative stress paralleled changes in [ 18 F]FSPG 6 accumulation, we next investigated the molecular mechanisms that linked these two outcomes. 7
Levels of xCT protein, the transporter component of heterodimeric system xc -, were unchanged by 8 either oxidizing or antioxidant treatments (Fig. 1C) , ruling out changes in transporter protein 9 expression as an explanation for the observed differences in [ 18 F]FSPG uptake. The extracellular 10 concentrations of the system xcsubstrates, cystine and glutamate, have previously been shown to 11 affect [ 18 F]FSPG cell uptake (26). Furthermore, both glutamate and cystine are substrates for GSH 12 biosynthesis. We therefore hypothesized that increased GSH biosynthesis under oxidative stress 13 would diminish intracellular pools of cystine and/or glutamate and thereby affect levels of 14 Fig. 3A . 16 17 The sensitivity of [ 18 F]FSPG retention to levels of intracellular glutamate was tested by incubating 18 cells in glutamine-free media. Removal of glutamine resulted in a rapid depletion of intracellular 19 glutamate, from 107 ± 21 nmol/mg protein to 46 ± 16 nmol/mg protein after 2h glutamine 20 withdrawal (p < 0.0001, n = 3; Supplementary Fig. S2) Fig. S2) . Redox 3 manipulation with TBHP, NAC or the combined treatment, however, had no effect on intracellular 4 or extracellular glutamate in A2780 cells ( Fig. 3B and C ; p > 0.05, n = 3-4), nor were there changes 5 in expression of glutaminase enzymes which serve as a major source of cellular glutamate through 6 glutaminolysis (Fig. 1C) . In contrast, intracellular cystine concentrations mirrored the pattern of 7 [ 18 F]FSPG accumulation (Fig. 3D) , with lowered cystine measured in lysates from TBHP-treated 8 cells, increased cystine present following NAC treatment, and intermediate levels seen after the 9 combined treatment. NAC treatment also dramatically decreased extracellular cystine levels ( Fig.  10   3E) , whereas TBHP had no such effect. In addition, [ 18 F]FSPG cell retention was markedly 11 dependent on the concentration of extracellular cystine (Supplementary Fig. S2) . 12 13 Oxidative stress decreases intracellular cystine via stimulation of GSH biosynthesis. 14 We next used isotopic tracing to identify the mechanism underlying the changes in cystine that 15 follow oxidative stress. We incubated A2780 cells in cystine-free media supplemented with [U-16 13 C6, U-15 N2]cystine to isotopically follow the fate of cystine through key metabolites in the GSH 17 biosynthetic pathway, shown in Fig. 4A . TBHP treatment resulted in a large and progressive 18 decrease in intracellular [U-13 C6, U-15 N2]cystine (Fig. 4B) , confirming our previous steady-state 19 measurements. Heavy isotope-labeled cysteine was also reduced upon TBHP treatment (Fig. 4C) , 20 however, a small increase in isotopic enrichment was seen for γ-glutamylcysteine ( Fig. 4D) and 21 reduced GSH (Fig. 4E) under these oxidizing conditions. Looking to the furthest point downstream 22 (Fig. 4F) , TBHP treatment resulted in increased isotopic enrichment of both single (M+4) and dual 23
Author Manuscript Published OnlineFirst on November 6, 2018; DOI: 10.1158/0008-5472. CAN-18-2634 (M+8) labeled GSSG, indicating that increased flux into GSH biosynthesis is at least partly 1 responsible for the decrease in intracellular cystine. Incorporation of two heavy-labeled cystines 2 into GSSG occurred at a slower rate than single label incorporation given the large preexisting 3 pool of unlabeled GSH, with elevated flux of cystine into M+8 GSSG following TBHP treatment 4 evident by 60 min (Supplementary Fig. S3 ). NAC-induced cystine changes were also investigated 5 using a steady-state approach with unlabeled cystine. Here, we found that the decrease in 6 extracellular cystine upon NAC treatment (Fig. 2D) was the result of a disulfide exchange reaction 7 in which cystine is largely replaced by a NAC-cysteine disulfide species (Supplementary Fig.  8   S4) . This disulfide exchange reaction also occurred intracellularly, as evidenced by the appearance 9 of the NAC-cysteine conjugate. intracellular markers of oxidative stress in A2780 ovarian cancer cells grown in culture. As shown 17
in Supplementary Fig. S5 In A2780 ovarian tumor-bearing mice, [ 18 F]FSPG PET was characterized by high uptake in the 1 tumor and pancreas, tissues with elevated system xc --expression. The remaining activity was 2 cleared via the urinary tract to produce excellent tumor-to-background contrast (Supplementary  3   Fig. S6) . A2780 tumor-bearing mice were subsequently treated with Doxil over a six day treatment 4 time course (Fig. 5A) , with tumor response to therapy imaged by [ 18 F]FSPG PET. Tumor growth 5 rate was unaffected by a single bolus of Doxil (Fig. 5B) , however a second round of treatment 6 resulted in a reduction in tumor volume between days 3 and 6, yielding tumors on day 6 that were 7 similar in volume to their original size prior to therapy. In tumors, total GSH dropped from 19.1 ± 8 2.3 nmol/mg protein to 12.6 ± 3.0 nmol/mg protein (p < 0.05) just 24 h post-Doxil treatment ( Fig.  9 5C), indicating changes in tumor redox status that precede, by two days, a reduction in tumor 10 volume indicative of chemotherapy response. Further changes in tumor redox status were seen in 11 the ratio of GSSG to GSH, which increased over the course of treatment from 0.010 ± 0.005 to 12 0.27 ± 0.18 after 6 days treatment (p < 0.01; Fig. 5D ). Doxil treatment increased levels of p53, and 13 to a lesser extent cleaved caspase-3, providing further evidence of a positive response to therapy 14 ( Supplementary Fig. S6) . Surprisingly, no increase in levels of the antioxidant transcription factor 15 Nrf2 or the GSH biosynthetic enzyme glutamate-cysteine ligase (GCL) were observed. There were 16 also no changes in tumor xCT protein levels with Doxil treatment (Supplementary Fig. S6) . 17 18 In tumors, [ 18 F]FSPG retention decreased by 42% just 24 h after Doxil treatment, from 4.35 ± 0.87 19 % ID/mL in untreated animals (Movie S1), to 2.25 ± 0.91 % ID/mL (p < 0.01; Fig. 5E, F and  20 Movie S2). This decrease in tumor-associated [ 18 F]FSPG coincided with Doxil-induced depletion 21 of GSH (Fig. 5C) , but occurred prior to any observable tumor shrinkage, (Fig. 5B) Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on November 6, 2018; DOI: 10.1158/0008-5472. CAN-18-2634 relative to untreated mice; Movie S3). Representative sagittal and axial images are shown in 1 Supplementary Fig. S6 . By comparison, [ 18 F]FDG uptake was unchanged after 24 h of treatment, 2 when tumor redox changes became apparent, but was significantly decreased at the 6 day time 3 point, from 4.85 ± 1.29 % ID/mL on D0 to 2.28 ± 1.23 % ID/mL on D6, when tumor shrinkage 4 was evident (p < 0.05; Supplementary Fig. S6) tumor retention provides an index of redox status through its sensitivity to levels of intracellular 7 cystine. System xc --derived cystine plays a central role in redox biochemistry. Indeed, 8 pharmacological inhibition of system xcresults in greatly reduced cellular GSH (37) and system 9 xcknock out mice show decreased levels of GSH in the blood (38). Intracellularly, system xc --10 derived cystine is rapidly reduced to cysteine, which itself plays a crucial role in antioxidant 11 processes. In addition to its role in GSH biosynthesis, cysteine can act as an antioxidant, protecting 12 the cell during conditions of GSH depletion (39) . Transmembrane cycling of the cystine-cysteine 13 redox pair is also important in maintenance of both intra-and extracellular redox homeostasis (40) . 14 Cystine levels therefore represent a point of convergence between multiple arms of the cell's 15 antioxidant system, making the responsiveness of [ 18 F]FSPG uptake to this amino acid a valuable 16 surrogate marker of oxidative stress. 17
18
The changes that we observe in [ 18 F]FSPG retention with oxidative stress can be understood by 19 considering the mechanism of system xctransport. The cystine/glutamate exchange activity of 20 system xcis mediated by the membrane concentration gradients of the exchanged species, 21 glutamate (high intracellular, low extracellular) and cystine (low intracellular, high extracellular) 22 (27) . Consequently, both amino acids are exchanged along their concentration gradients, with 23
Author Manuscript Published OnlineFirst on November 6, 2018; DOI: 10.1158/0008-5472. CAN-18-2634 glutamate leaving and cystine entering the cell. [ 18 F]FSPG acts as a third exchange partner in this 1 exchange system, and as expected, its cell retention was influenced by levels of cystine or 2 glutamate. Additionally, both cystine and glutamate can act competitively (41), preventing 3 interaction of [ 18 F]FSPG with system xc -(26). Thus, there are two potential mechanisms by which 4 changes in levels of cystine or glutamate could affect [ 18 F]FSPG retention: through changes in the 5 amino acid gradients across the plasma membrane, or through altered levels of competition at the 6 site of the transporter. A schematic depicting these processes is shown in Fig. 3A . Kinetic analysis 7 of dynamic imaging data may help further elucidate the mechanism of [ 18 F]FSPG trapping and 8 retention, taking into account both cellular transport and blood flow. Our findings confirm the 9 sensitivity of [ 18 F]FSPG retention to changes in levels of either amino acid ( Fig. 3 and  10   Supplementary Fig. S2) . However, during oxidative stress glutamate levels remain unchanged, 11
implicating the observed depletion of intracellular cystine as the factor mediating changes in 12 [ 18 F]FSPG uptake. 13 14 Using a metabolomics approach, we explored the connection between oxidative stress and changes 15 in cystine metabolism. We found that the decrease in intracellular cystine following TBHP 16 treatment was the result of an increase in flux of cystine through the GSH biosynthetic pathway. 17
Using heavy isotope-labeled cystine, TBHP produced a selective isotopic enrichment of GSSG, 18
indicating increased GSH biosynthesis and subsequent oxidation. This finding provides a direct 19 mechanistic connection between oxidative stress, intracellular cystine levels and [ 18 F]FSPG 20 uptake. Isotopic enrichment of reduced GSH was only marginally increased in stressed over 21 untreated cells, probably reflecting both the far larger GSH pool compared to GSSG (100) and 22 the relatively short enrichment time of 60 min. Whereas oxidative stress changed only intracellular 23
Author Manuscript Published OnlineFirst on November 6, 2018; DOI: 10.1158/0008-5472. CAN-18-2634 cystine levels, the antioxidant NAC altered both intracellular and extracellular concentrations of 1 cystine. The extracellular changes were accounted for by a disulfide exchange reaction between 2 NAC and cystine, which converted virtually all extracellular cystine to free cysteine and a NAC-3 cysteine mixed disulfide species. NAC also resulted in an increase in intracellular cystine, 4 potentially by providing cysteine through deacetylation of NAC (42) . 5 6 Unlike other redox imaging methods currently under development, which monitor ROS levels via 7 oxidation/reduction of a probe compound, [ 18 F]FSPG PET does not provide an index ROS 8 production per se. Rather, it provides a measure of cellular antioxidant response (i.e. increased 9 GSH biosynthesis). An advantage of this approach is that adaptive changes such as increased GSH 10 biosynthesis represent processes down-stream of ROS and are therefore more proximal to desired 11 outcomes such as cell death. Indeed, rather than killing cells directly, ROS induce intervening 12 redox biochemical changes, including GSH depletion and alteration of thiol/disulfide balance, 13 which in turn trigger apoptosis (43). While we have provided evidence that glutamate levels are 14 unaltered during oxidative stress, it is possible that non-redox related changes in glutamate, such 15 as those associated with glutamate utilization in anaplerosis and energy metabolism, could 16 confound interpretation of [ 18 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on DOI: 10.1158 /0008-5472.CAN-18-2634 Several therapeutic strategies, including chemotherapy, radiotherapy and targeted therapies act in-1 part to disrupt tumor redox homeostasis (44) (45) (46) . As a consequence, the emergence of resistance 2 to these therapies is often accompanied by enhanced antioxidant production (13). Specifically, 3 doxorubicin's therapeutic mechanism of action involves both the direct and indirect induction of 4 oxidative stress oxidative stress via redox cycling, production of superoxide and hydrogen 5 peroxide, and DNA damage (47). Tumor-associated [ 18 F]FSPG was sensitive to doxil-induced 6 changes in tumor redox status which occurred soon after the initiation of treatment but prior to 7 measurable changes in tumor volume ( Fig. 5) . In particular, Doxil caused a depletion of tumor 8 GSH potentially as either the direct result of Doxil-induced oxidative stress or via formation and 9 efflux of Doxil-GSH conjugate by the multidrug-resistance-associated proteins (MRPs) (48). GSH 10 depletion by either mechanism could presumably affect intracellular cystine levels by influencing 11 de novo GSH synthesis. Therefore, [ 18 F]FSPG could facilitate a precision medicine approach in 12 which drug response could be predicted in individual patients based on redox response 13 measurements. Moreover, given that steady-state levels of GSH are known to correlate well with 14 drug resistance, a dynamic marker of GSH biosynthetic flux may provide further insights into drug 15 resistance mechanisms in vivo. 16
17
In conclusion, this study demonstrates in preclinical models of cancer, that a PET radiotracer used 18 in clinical investigations is sensitive to tumor redox status. Oxidative stress-induced changes in 19 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on November 6, 2018; DOI: 10.1158/0008-5472. CAN-18-2634 Intracellular retention of [ 18 F]FSPG following the above treatments. Scatter plot points represent 1 independent experiments, each performed as a single measurement. (C) Correlation between 2 CellROX Green fluorescence and intracellular [ 18 F]FSPG accumulation. Broken lines represent 3 the 95% confidence interval of the best fit line. Data are presented as mean ± SD. * p < 0.05, ** p 4 < 0.01, *** p < 0.001, single sample t test (versus unity). For scatter plots, an F test was used to 5 determine whether the line of best fit was significantly different from zero. 
